壽仙谷(603896.SH):浙江壽仙谷藥房已按約定一次性支付330萬元股權轉讓款
格隆匯5月15日丨壽仙谷(603896.SH)公佈,2025年4月23日,壽仙谷投資和浙江壽仙谷藥房共同簽署了《股權轉讓協議》。截至目前,浙江壽仙谷藥房已按約定一次性支付330.00萬元股權轉讓款,杭州壽仙谷藥房已完成相關工商變更登記手續。本次股權收購事項已完成,浙江壽仙谷藥房持有杭州壽仙谷藥房100%的股權,杭州壽仙谷藥房已成爲公司的全資孫公司,納入公司合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.